Status:

COMPLETED

Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)

Lead Sponsor:

Harvard School of Public Health (HSPH)

Collaborating Sponsors:

National Cancer Institute (NCI)

Botswana Harvard AIDS Institute Partnership

Conditions:

Breast Neoplasms

Lymphoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Prospective feasibility and validation study of a novel, near-to-care modality for diagnosis of malignancy among cancer suspects.

Detailed Description

Prospective feasibility and validation study of a novel contrast microhalography (CEM) device for diagnosis of malignancy in Botswana. Consenting patients identified by their providers as requiring a ...

Eligibility Criteria

Inclusion

  • Botswana citizen
  • Age 18 years or older
  • Able and willing to provide informed consent
  • Undergoing diagnostic procedure for palpable abnormality (biopsy, node/mass resection, or fine-needle aspirate) for diagnosis of possible lymphoid malignancy or breast cancer

Exclusion

  • Involuntary incarceration (prison, jail, etc.)
  • Procedures involving internal organs or locations expected to have elevated risk of complication
  • Increased risk for severe bleeding as defined as known hemophilia or other bleeding disorder, use of anticoagulants in past week (not including aspirin or other NSAIDS), advanced liver disease, or other condition determined by clinician to significantly increase bleeding risk of procedure
  • Known pregnancy
  • Critical illness as defined by current intensive care admission, hypotension (systolic BP\<100mmHg), hypoxemia (O2 saturation \<94% on room air), or other condition determined by clinician to significantly decrease physiologic tolerance of procedure
  • Other condition felt by the clinician performing procedure to significantly increase risk of procedure

Key Trial Info

Start Date :

August 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 20 2021

Estimated Enrollment :

270 Patients enrolled

Trial Details

Trial ID

NCT04119154

Start Date

August 1 2019

End Date

September 20 2021

Last Update

May 2 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Botswana Harvard AIDS Institute

Gaborone, Botswana